Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POTAMI-61: RVU120 monotherapy and combination with ruxolitinib in intermediate/high-risk myelofibrosis
2024-511688-27-00Phase 2Completed
- Sponsor
- Ryvu Therapeutics
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of rvu120 in primary myelofibrosis (PMF) and myelofibrosis (MF) (3 cohorts), sponsored by Ryvu Therapeutics. Primary endpoint: Spleen Volume Reduction ≥35% at Week 24. Started Aug 2024; status: completed.
02
Drugs
rvu120
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on 2024-511688-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511688-27-00.